PDE5A and cancer: For Stage I cancers, PDE5 inhibitor exposure was associated with significantly improved 3- and 5-year OS compared with controls (1-year OS not measurable; 3‐year OS 96.1% vs 92.6%, p=0.03; 5‐year OS 92.1% vs 87.6%, p=0.02; HR, 0.57 [95% CI, 0.35–0.93]; Figure 1).